Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Queensland Health
Merck
Baxter
Citi
Fuji
Fish and Richardson
Accenture
McKesson

Generated: July 23, 2018

DrugPatentWatch Database Preview

DEXILANT SOLUTAB Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Dexilant Solutab, and when can generic versions of Dexilant Solutab launch?

Dexilant Solutab is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are fifteen patents protecting this drug.

This drug has two hundred and forty-five patent family members in thirty-nine countries.

The generic ingredient in DEXILANT SOLUTAB is dexlansoprazole. There are seventeen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the dexlansoprazole profile page.
Summary for DEXILANT SOLUTAB
Drug patent expirations by year for DEXILANT SOLUTAB
Medical Subject Heading (MeSH) Categories for DEXILANT SOLUTAB
Synonyms for DEXILANT SOLUTAB
(+)-(R)-Lansoprazole
(+)-2-((R)-{(3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl}sulfinyl)-1H-benzimidazole
(+)-lansoprazol
(r)-(+)-lansoprazole
(R)-(+)2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzimidazole
(R)-2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
(R)-2-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)METHYLSULFINYL)-1H-BENZO[D]IMIDAZOLE
(R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole
(R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]benzimidazole
(R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
(R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole
(R)-Lansoprazole
138530-94-6
1H-Benzimidazole, 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-
2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
2-[(R)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole
2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole
2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl]-1H-1,3-benzodiazole
2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methane}sulfinyl]-1H-1,3-benzodiazole
3B1-001176
AB01563023_01
AB01563023_02
AC-26449
AK170558
AKOS025290765
AN-31849
AS-18086
CCG-213301
CHEBI:135931
CHEMBL1201863
CS-2820
D06YYD
D08903
DB05351
dexilant
dexlansoprazole
Dexlansoprazole (INN/USAN)
Dexlansoprazole [USAN:INN]
Dexlansoprazole sesquihydrate
FT-0670721
GTPL5487
HE065042
HMS3652C14
HY-13662B
Kapidex
KS-00000PLS
KS-1075
MFCD13196699
MJIHNNLFOKEZEW-RUZDIDTESA-N
MolPort-002-885-834
PB33188
Q-1374
R- -Lansoprazole
R-(+)-LANSOPRAZOLE
r-lansoprazole
s4099
SC-71768
SCHEMBL44975
T 168390
T-168390
TAK 390
TAK-390
TAK-390MR
UNII-0K5C5T2QPG component MJIHNNLFOKEZEW-RUZDIDTESA-N
UNII-UYE4T5I70X
UYE4T5I70X
W0028
ZINC599734

US Patents and Regulatory Information for DEXILANT SOLUTAB

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa DEXILANT SOLUTAB dexlansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 208056-001 Jan 26, 2016 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Takeda Pharms Usa DEXILANT SOLUTAB dexlansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 208056-001 Jan 26, 2016 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Takeda Pharms Usa DEXILANT SOLUTAB dexlansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 208056-001 Jan 26, 2016 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Takeda Pharms Usa DEXILANT SOLUTAB dexlansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 208056-001 Jan 26, 2016 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for DEXILANT SOLUTAB

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,884,019 Benzimidazole compound crystal ➤ Sign Up
9,889,152 Multiple PPI dosage form ➤ Sign Up
7,790,755 Controlled release preparation ➤ Sign Up
7,339,064 Benzimidazole compound crystal ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for DEXILANT SOLUTAB

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90004-7 Sweden ➤ Sign Up PRODUCT NAME: DEXLANSOPRAZOL; REG. NO/DATE: 47912, 47913, 47914 20130919
1129088/01 Switzerland ➤ Sign Up PRODUCT NAME: DEXLANSOPARAZOL; REGISTRATION NO/DATE: SWISSMEDIC 62993 09.05.2014
2014014,C1129088 Lithuania ➤ Sign Up PRODUCT NAME: DEXLANSOPRAZOLUM; REGISTRATION NO/DATE: LT/1/13/3415/001 - LT/1/13/3415/004, 2013 10 31 LT/1/13/3416/001 - LT/1/13/3416/004 20131031
14/008 Ireland ➤ Sign Up PRODUCT NAME: DEXLANSOPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: PA1864/001/001-002;PA1864/002/001-002 20131125; FIRST REGISTRATION NO/DATE: 47911 47912 47913 47914 20130919
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Chinese Patent Office
McKinsey
McKesson
Fish and Richardson
US Army
Colorcon
Farmers Insurance
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.